Another repurposed drug bites the dust in Covid-19 as Angion bails on organ damage drug effort

Since the early days of the pandemic, drugmakers have taken a broad approach to repurposing other drugs in their pipeline against severe Covid-19 — a mission that has met, with a couple notable exceptions, little tangible success. Now, another small biotech is throwing its hands up after its organ damage...

Click to view original post